Lamivudine Milpharm (Lamivudine)

Lamivudine is a nucleoside analogue that mimics natural nucleosides. It is incorporated by HIV reverse transcriptase into viral DNA, where it lacks a 3'-hydroxyl group, causing premature chain termination and preventing further viral DNA synthesis.

The appropriate dose of lamivudine is determined by the prescribing healthcare professional based on the specific indication, patient characteristics, and any concomitant medications. Dosage regimens may differ between HIV and hepatitis B treatment protocols.

Safety data for lamivudine during pregnancy and lactation are limited. Prescribers should weigh the potential benefits against possible risks and consider current clinical guidelines when deciding to use lamivudine in pregnant or nursing individuals.

To place an order, submit an enquiry on the Lamivudine Milpharm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class. Compared with other NRTIs such as tenofovir, lamivudine generally has a favorable renal safety profile but may have a lower barrier to resistance when used without a potent companion drug. Choice of agent depends on individual patient factors and treatment guidelines.

Lamivudine tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Lamivudine is administered orally, usually as a tablet taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare provider and should not alter the timing or skip doses without medical advice.

Serious adverse events, although rare, include lactic acidosis, severe hepatotoxicity, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, and bone marrow suppression. Patients should seek immediate medical attention if they experience unexplained abdominal pain, rapid weight loss, severe fatigue, or skin rash.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in patients where the risk‑benefit assessment does not support its use.